Sichuan Kelun-Biotech Biopharmaceutical's (HKG:6990) new indication application for sacituzumab tirumotecan was accepted for review by China's National Medical Products Administration, according to a Friday Hong Kong bourse filing.
The application is for the drug in combination with pembrolizumab as first-line treatment for adult patients with locally advanced or metastatic non-small cell lung cancer.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.